A meta-meta-analysis: Evaluation of meta-analyses published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19

Mehri Bemani Naeini; Mahdieh Sahebi; Fateme Nikbakht; Zahra Jamshidi; Mahnaz Ahmadimanesh; Maryam Hashemi; Javad Ramezani; Hamid Heidarian Miri; Rezvan Yazdian-Robati

doi:10.1016/j.obmed.2021.100323

A meta-meta-analysis: Evaluation of meta-analyses published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19

Obes Med. 2021 Mar:22:100323. doi: 10.1016/j.obmed.2021.100323. Epub 2021 Jan 23.

Authors

Mehri Bemani Naeini¹, Mahdieh Sahebi², Fateme Nikbakht², Zahra Jamshidi³, Mahnaz Ahmadimanesh⁴, Maryam Hashemi¹, Javad Ramezani⁵, Hamid Heidarian Miri², Rezvan Yazdian-Robati⁶

Affiliations

¹ Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
² Social Determinants of Health Research Center, Department of Epidemiology, Mashhad University of Medical Sciences, Mashhad, Iran.
³ Department of Medicinal Chemistry, Mashhad University of Medical Sciences, Mashhad, Iran.
⁴ Food and Drug Vice Presidency, Mashhad University of Medical Sciences, Mashhad, Iran.
⁵ Department of Cardiology, Atherosclerosis Prevention Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁶ Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Abstract

On January 2020, WHO confirmed the epidemic outbreak of SARS-CoV-2 as a Health Emergency of International Concern. The aim of this meta-meta-analysis is quantifying meta-analytic findings on the association of cardiovascular disease (CVD) comorbidities and COVID-19 severity. Findings suggest that chances of getting severe COVID-19 disease in patients with CVD is greater than those without CVD. Also, prevalence of CVD in patents with COVID-19 is 0.08 (95% CI = 0.07-0.08). The OR as 3.44 indicates that the odds of getting severe COVID-19 is more than 3 times higher in those with CVD. Also, prevalence of hypertension in patient with COVID-19 is 0.27 (95%CI = 0.27-0.28) and the OR as 2.68 indicates that the odds of getting severe COVID-19 in cases with high blood pressure is more than 2.5 times higher than those without hypertension. It is rational to suppose that persons with coronary artery disease are prone to severe viral infection thereby, guideline-directed diagnosis and medical therapy is vital in CVD patients.

Keywords: ACE2, angiotensin converting enzyme 2; ACS, Acute coronary syndrome; ARDS, Acute respiratory distress syndrome; CHD, Coronary heart disease; COVID-19; COVID-19, Coronavirus disease-2019; CVD, Cardiovascular disease; Cardiovascular; Clinical characteristics; Heart damage; Hypertension; ICU, Intensive care unit; Meta-meta-analysis; NHC, National Health Commission of China; Prevalent comorbidity; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Underlying disease.

Publication types

Review